TONELLO, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.217
AS - Asia 1.529
EU - Europa 893
AF - Africa 365
SA - Sud America 352
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 12
Totale 6.403
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.017
SG - Singapore 575
CN - Cina 319
BR - Brasile 218
HK - Hong Kong 153
IT - Italia 126
DE - Germania 120
VN - Vietnam 109
FI - Finlandia 79
GB - Regno Unito 61
NL - Olanda 53
SE - Svezia 45
FR - Francia 38
JP - Giappone 35
PL - Polonia 34
AR - Argentina 29
ID - Indonesia 28
RU - Federazione Russa 28
MX - Messico 25
IN - India 21
UA - Ucraina 21
ZA - Sudafrica 21
TR - Turchia 19
CZ - Repubblica Ceca 18
UY - Uruguay 17
BA - Bosnia-Erzegovina 16
BE - Belgio 16
MR - Mauritania 16
VE - Venezuela 16
AT - Austria 15
CR - Costa Rica 15
DZ - Algeria 15
ES - Italia 15
IQ - Iraq 15
PE - Perù 15
CI - Costa d'Avorio 14
CO - Colombia 14
IE - Irlanda 14
KR - Corea 14
RS - Serbia 14
KZ - Kazakistan 13
LC - Santa Lucia 13
MD - Moldavia 13
PT - Portogallo 13
PY - Paraguay 13
TW - Taiwan 13
CA - Canada 12
IR - Iran 12
SN - Senegal 12
SO - Somalia 12
TT - Trinidad e Tobago 12
AL - Albania 11
AU - Australia 11
CD - Congo 11
ET - Etiopia 11
ML - Mali 11
MZ - Mozambico 11
NI - Nicaragua 11
RE - Reunion 11
SD - Sudan 11
SI - Slovenia 11
UZ - Uzbekistan 11
AE - Emirati Arabi Uniti 10
BF - Burkina Faso 10
BJ - Benin 10
GH - Ghana 10
GP - Guadalupe 10
JO - Giordania 10
KH - Cambogia 10
MG - Madagascar 10
MK - Macedonia 10
MU - Mauritius 10
NC - Nuova Caledonia 10
NG - Nigeria 10
SA - Arabia Saudita 10
TJ - Tagikistan 10
YE - Yemen 10
BY - Bielorussia 9
CG - Congo 9
CH - Svizzera 9
CL - Cile 9
CU - Cuba 9
EE - Estonia 9
GE - Georgia 9
GF - Guiana Francese 9
GT - Guatemala 9
HN - Honduras 9
HU - Ungheria 9
IL - Israele 9
IS - Islanda 9
KG - Kirghizistan 9
LU - Lussemburgo 9
MA - Marocco 9
TH - Thailandia 9
AD - Andorra 8
AF - Afghanistan, Repubblica islamica di 8
AZ - Azerbaigian 8
BB - Barbados 8
BG - Bulgaria 8
CM - Camerun 8
Totale 6.043
Salva come PNG Salva come JPEG
Città #
Fairfield 433
Ashburn 428
Singapore 313
Chandler 277
Woodbridge 232
Houston 189
Ann Arbor 153
Hong Kong 146
Seattle 134
Cambridge 129
Wilmington 115
Beijing 106
Santa Clara 81
Boardman 58
Munich 51
San Diego 49
Los Angeles 44
Princeton 41
Padova 39
Des Moines 36
Medford 35
Ho Chi Minh City 33
Jacksonville 30
Roxbury 28
New York 27
Helsinki 26
Turku 24
Nanjing 22
Bytom 21
Hanoi 20
Dong Ket 16
Nouakchott 16
Chicago 15
Abidjan 14
Buffalo 14
Montevideo 14
San José 14
Castries 13
Johannesburg 13
Dakar 12
London 12
Addis Ababa 11
Bamako 11
Milan 11
Tokyo 11
Amman 10
Cotonou 10
Kinshasa 10
Lima 10
Managua 10
Mito 10
Nanchang 10
Noumea 10
Antananarivo 9
Dushanbe 9
Falkenstein 9
Havana 9
Hefei 9
Khartoum 9
Ouagadougou 9
Phnom Penh 9
Poplar 9
São Paulo 9
Tashkent 9
Tsukuba 9
Accra 8
Andorra la Vella 8
Baku 8
Bridgetown 8
Dearborn 8
Dublin 8
Frankfurt am Main 8
Guangzhou 8
Maputo 8
Nuremberg 8
Stockholm 8
Vienna 8
Vientiane 8
Warsaw 8
Washington 8
Bishkek 7
Brno 7
Brooklyn 7
Chaguanas 7
Council Bluffs 7
Dallas 7
Kampala 7
Kigali 7
Lusaka 7
Manchester 7
Minsk 7
Nairobi 7
Nassau 7
Orem 7
Reykjavik 7
Rome 7
Roseau 7
Sanaa 7
Tallinn 7
Zhengzhou 7
Totale 3.965
Salva come PNG Salva come JPEG
Nome #
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report 204
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 199
Plasma exchange effectively removes 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block. 194
Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study 189
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 188
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 185
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 185
Prognosis of scleroderma renal crisis: a long-term observational study. 184
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. 175
Clinical and laboratory characteristics of isolated lupus anticoagulants 167
Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 165
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 164
Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis. 161
The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome 159
Antiphosphatidylserine/prothrombin antibodies in antiphospholipid syndrome with intrauterine growth restriction and preeclampsia 153
Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block 152
Clinical value of anti-domain I-β2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study 148
Hypertension negatively affects the pregnancy outcome in patients with antiphospholipid syndrome. 146
Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients 142
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study 141
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 140
Impact of COVID-19 and COVID-19 vaccination on high-risk patients with Antiphospholipid Syndrome: a nationwide survey 138
Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. 138
Detection of autoantibodies to the p200-epitope of SSA/Ro52 antigen. A comparison of two laboratory assays 137
IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. 137
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. 136
Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome 131
The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. 128
IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis 126
Unstabilized DNA breaks in lymphocytes of patients with different subsets of systemic sclerosis 125
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 124
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 123
[Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases]. 119
Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. 117
Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity? 113
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. 110
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets 106
Risk-based secondary prevention of obstetric antiphospholipid syndrome. 105
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies 105
Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome 101
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases 101
Unstabilized DNA breaks in lymphocytes of patients with systemic sclerosis. 98
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets 95
Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature 90
Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature 86
Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study 76
Human epididymis protein 4 as a biomarker of interstitial lung disease in patients with idiopathic inflammatory myopathies 52
Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome 1
Totale 6.459
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.969
article - articoli 21.969
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.938
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021241 0 0 0 0 0 21 12 43 51 22 60 32
2021/2022579 22 54 87 38 20 36 24 61 27 12 47 151
2022/2023462 103 72 4 63 63 57 7 35 33 5 18 2
2023/2024324 13 53 41 26 22 51 26 14 13 5 25 35
2024/20251.131 4 62 52 51 122 58 60 85 74 38 211 314
2025/20262.473 271 333 572 744 450 103 0 0 0 0 0 0
Totale 6.459